(18)F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)

INTRODUCTION: Regorafenib is a multikinase inhibitor approved for the treatment of metastatic colorectal cancer (mCRC). Despite providing a statistically significant survival benefit, a substantial number of patients fail to respond to or continue with treatment, which has resulted in an unmet clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Masato, Satake, Hironaga, Sagawa, Tamotsu, Takagane, Akinori, Sekikawa, Takashi, Oguchi, Kazuhiro, Kaji, Tomohito, Takeuchi, Masahiro, Ichikawa, Wataru, Fujii, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593152/
https://www.ncbi.nlm.nih.gov/pubmed/34626349
http://dx.doi.org/10.1007/s40487-021-00173-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593152/
https://www.ncbi.nlm.nih.gov/pubmed/34626349
http://dx.doi.org/10.1007/s40487-021-00173-1

Ejemplares similares